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Abstract
Comprehension of randomization is a vital, but understud-
ied, component of informed consent to participate in can-
cer randomized clinical trials (RCTs). This study examines 
patient comprehension of the randomization process as 
well as sources of ongoing uncertainty that may inhibit a 
patient’s ability to provide informed consent to participate 
in RCTs. Cancer patients living in rural Appalachia who were 
offered an opportunity to participate in a cancer treat-
ment RCT completed in-depth interviews and a brief sur-
vey. No systematic differences in randomization compre-
hension between patients who consented and those who 
declined participation in a cancer RCT were detected. Com-
prehension is conceptually distinct from uncertainty, with 
patients who had both high and low comprehension ex-
periencing randomization-related uncertainty. Uncertainty 
about randomization was found to have cognitive and af-
fective dimensions. Not all patients enrolling in RCTs have 
a sufficient understanding of the randomization process 
to provide informed consent. Healthcare providers need 
to be aware of the different types of randomization-re-
lated uncertainty. Efforts to improve informed consent to 
participate in RCTs should focus on having patients teach 
back their understanding of randomization. This practice 
could yield valuable information about the patient’s cog-
nitive and affective understanding of randomization as 
well as opportunities to correct misperceptions. Education 
about RCTs should reflect patient expectations of individ-
ualized care by explaining how all treatments being com-
pared are appropriate to the specifics of a patient’s disease.
Keywords: Cancer clinical trials, Oncology research, Health 
disparities, Randomization, Uncertainty, Decision making 
Background
Randomized clinical trials (RCTs) are the gold standard 
for evaluating emerging discoveries in cancer treatments 
and, as such, the approval of new cancer treatments de-
pends on enrolling a sufficient number of participants in 
a timely manner [1]. Unfortunately, advances in cancer 
treatment are often delayed due to slow rates of RCT ac-
crual, particularly among vulnerable populations such as 
rural residents [2].
While enrollment in cancer RCTs is an important indi-
cator of the extent to which vulnerable populations have 
the ability to access state-of-science treatment, another 
factor that should be considered is a patient’s ability to 
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give informed consent to treatment [3]. Informed consent 
in the context of RCTs is particularly challenging because 
patients must understand both the nature of their disease 
and associated therapies as well as the role of probability 
in experimental research design in order to make an in-
formed decision about their healthcare. Although strate-
gies for promoting patient understanding of a cancer diag-
nosis, prognosis, and conventional treatment options are 
well documented [4–6], more research is needed on patient 
comprehension of scientific research design and random-
ization-related uncertainty in the context of cancer RCTs.
Randomization Comprehension
Given the importance of randomization in the informed 
consent process, there is a growing body of research fo-
cused on how people understand randomization and their 
attitudes about using randomization procedures to de-
termine medical treatment in RCTs [7–10]. Kerr and col-
leagues showed that college students accurately identi-
fied methods of random allocation (e.g., flip of a coin), but 
had negative attitudes toward using these methods to de-
termine medical treatment [7]. Similarly, Appalachian can-
cer patients and their caregivers understood randomiza-
tion conceptually, with different forms of gambling (e.g., 
lottery) being the most readily accessible example of ran-
dom selection [8]. Unfortunately, comprehension of ran-
domization may not be better among patients enrolled in 
cancer RCTs than the general public.
Randomization-Related Uncertainty
The challenge of explaining randomization to patients lies 
in the high degree of uncertainty inherent in the concept. 
In most medical contexts, healthcare providers engage in 
educational efforts to reduce a patient’s uncertainty about 
their illness. Illness uncertainty exists when the elements of 
a health situation are perceived as complicated, ambigu-
ous, variable, or probabilistic [11–13]. In many healthcare 
situations, education should decrease some forms of un-
certainty [14]. However, increased knowledge about ran-
domization cannot be expected to decrease uncertainty 
because the relationship between uncertainty and prob-
ability is curvilinear [13]. Uncertainty is lowest when indi-
viduals perceive the probability of a certain event as 0 or 
100 % and highest when it is 50 %. Thus, a patient with 
high comprehension of randomization enrolled in a two-
arm RCT should have a very high degree of uncertainty 
regarding the treatment she or he will receive. The unique 
relationship between comprehension and uncertainty in 
the cancer RCT context is important to explore because of 
the potentially significant implications for patient well-be-
ing as well as willingness to participate in medical research. 
As such, the purpose of the current study is to explore the 
relationship between comprehension and uncertainty, par-
ticularly as related to cancer RCT participation among an 
underserved and highest risk population.
Methods
Participants
Participants included 49 patients who were offered a can-
cer treatment RCT within the last 2 years and lived in or 
were treated for cancer in 1 of 32 Appalachian Ohio coun-
ties. Patients were recruited from a large, urban compre-
hensive cancer center (n = 17, 35 %) and four rural com-
munity cancer centers (n = 32, 65 %). The sample ranged 
in age from 33 to 79 years (M = 59.67, SD = 11.46) and 
was predominately female (n = 29; 59 %). Eleven partici-
pants did not enroll in a RCT; among these, ten were fe-
male (see Table 1). Interview data from three participants 
were eliminated from further analysis because they were 
offered non-RCT studies.
Procedure
The protocol approved by the university Institutional Re-
view Board entailed clinic staff identifying patients who 
had been offered an RCT in the past 2 years and lived in 
(or were treated) in an Appalachian county. Researchers 
mailed patients a recruitment letter signed by their treat-
ing physician. For three clinics, a researcher conducted 
follow-up phone calls to provide additional study infor-
mation and schedule interviews for those who agreed to 
participate. Semi-structured interviews were conducted 
by a trained research team member, were audio-recorded, 
and ranged from 30 min to 3 h in length. Interviews were 
conducted face-to-face at a location of the participant’s 
choice (e.g., home, hospital treatment room). After the in-
terview, participants completed a brief, self-administered 
survey and were remunerated US$30.00 for their time. The 
survey included five true/false items measuring random-
ization comprehension [15]. Participants received 1 point 
for each item answered correctly (range 0–5). Responses 
were summed to create a Randomization Comprehension 
Index (RCI; Table 2).
Data Analysis
The interview audio files were uploaded to a password-
protected computer, transcribed verbatim, and imported 
into NVivo 10. Transcripts were read multiple times by the 
principle investigator (J. L. K.) and three additional mem-
bers of the data analysis team to familiarize themselves 
with the content. Four authors conducted data analysis 
through an iterative combination of independent and 
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collaborative coding over a period of 16 weeks [16]. First, 
thought units pertaining to uncertainty were identified and 
open-coded as a team. Second, transcripts were open-
coded independently followed by weekly meetings to 
compare the textual composition and conceptual label-
ing of thought units in each transcript, discuss discrepan-
cies, and negotiate agreement [17, 18]. Third, axial coding 
was used to compare codes within and across transcripts, 
resulting in the creation of categories. A codebook was 
created and continually refined throughout the process 
that included conceptual labels, definitions, examples, and 
negative cases for each category. The resulting categories 
are discussed in detail in the following section.
There were a number of measures taken throughout the 
data collection and analysis process to ensure the trust-
worthiness of the findings [19]. Credibility was enhanced 
through triangulation, in that the textual composition and 
labeling of codes were agreed upon by at least two (and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
up to four) investigators. Dependability and confirmability 
were ensured through extensive theoretical and process 
memoing. Our audit trail includes memos for each inter-
view (created during data collection) and each transcript 
(created during data analysis). Furthermore, the team kept 
a memo describing key decisions and developments in the 
data analysis process.
Results and Interpretations
Randomization Comprehension and RCT Participation
Participants were divided into high and low randomiza-
tion comprehension groups based on their RCI score (see 
Table 2). High comprehension patients had an overall RCI 
score of 4 or 5 (n = 18; 39 %). Low comprehension patients 
had an overall RCI score of 3 or lower (n  = 28; 61 %). A 
goodness-of-fit (chi-square) analysis found no statistically 
significant differences between the RCI scores of patients 
who participated in a RCT as compared to those who de-
clined (see Table 3).
Randomization Comprehension and Uncertainty
Overall, comprehension of randomization (as measured 
by the RCI) was conceptually distinct from uncertainty, 
 
 
 
 
 
 
 
 
 
Table 1. Participant characteristics (n = 49)
Characteristic Number (%)
Sex
 Female 29 (59)
 Male 20 (41)
Race
 White 47 (96)
 Asian/Pacific islander 1 (2)
 Unreported 1 (2)
Participated in a RCT*
 Yes 35 (71)
 No 11 (22)
 Ineligible (offered a non-RCT study) 3 (6)
Cancer type*
 Breast 19 (39)
 Multiple myeloma 9 (18)
 Prostate 7 (14)
 Colon 6 (12)
 Lung 5 (10)
 Other 3 (6)
Annual income below US$49,000
 Yes 23 (50)
 No 23 (50)
Health insurance
 None 3 (6)
 Medicaid/Medicare 19 (39)
 Insured through employer 24 (49)
 Other 3 (6)
Education
 8th grade through some high school 4 (8)
 High school diploma or equivalent 19 (39)
 Vocational training/associates 17 (35)
 College graduate or more 9 (18)
*Values do not equal 100 % due to rounding
Table 2. Randomization Comprehension Index (RCI) items (n = 46)
Question                                                    Number (% correct)
RCI 1: In a clinical trial, randomization  34 (74 %) 
means that a patient is just as likely to  
get one treatment as another 
RCI 2: Randomization means that patients  33 (72 %) 
in a clinical trial are allowed to choose a  
treatment out of a list of options. 
RCI 3: Doctors who place their patients in  29 (63 %) 
clinical trials often choose the treatment  
that their patients should receive. 
RCI 4: In a clinical trial, one way to decide a  8 (17 %) 
patient’s treatment would be to toss a coin. 
RCI 5: The goal of a clinical trial is to match  22 (48 %) 
people to the best treatment for them 
Table 3. Randomization Comprehension Index scores of RCT 
participants versus nonparticipants
RCI Score                               Clinical trial   Total
 Yes No 
0–3 items correct 21 7 28
4–5 items correct 14 4 18
χ2 (1, n = 46) = .05, p = .83
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with patients at all levels of comprehension experiencing 
randomization-related uncertainty. However, patients de-
scribed two different types of uncertainty associated with 
the randomization process: (1) cognitive dimensions and 
(2) affective dimensions.
Cognitive Dimensions of Uncertainty about 
Randomization
Cognitive dimensions of uncertainty were thought units 
pertaining to perceived ambiguity about procedural as-
pects of randomization, such as assignment to treatment 
groups and probability of receiving effective treatment. Pa-
tients reported that their oncologists used a variety of de-
scriptions for explaining randomization to treatment arms, 
including flipping a coin, lottery process, and a computer 
(described below). Many patients struggled with these ex-
planations because they could not visualize the procedures 
being used to assign patients to treatment. For example, 
Jeanine, a patient with low comprehension of randomiza-
tion (RCI = 2), agreed to participate in an RCT. When ran-
domization was explained to her, she laughed and said, 
“You’re gonna put my name in a hat and draw us out and 
see which one I’m gonna get?” As illustrated by this quote, 
patients recognized these explanations of randomization as 
metaphorical in that researchers would not be literally flip-
ping coins or drawing slips of paper out of a hat in order to 
assign them to their treatment. However, using metaphors 
to describe the process did little to reduce patient uncer-
tainty about who would be determining which treatment 
they would receive or how that decision would be made.
Some healthcare providers tried to convey the idea that 
a patient’s treatment is chosen randomly by a computer. 
However, this explanation was also associated with uncer-
tainty. Patients are accustomed to computers being used to 
deliver highly individualized medical care, such as record-
ing their medical history through electronic medical records. 
Given that computers are typically used to provide individ-
ualized patient care, such as identify whether a patient is at 
risk for potential drug interactions, patients had difficulty 
understanding why the computer would not use the infor-
mation in their medical record to match them to the best 
possible treatment. To illustrate, Alice agreed to participate 
in a RCT. Despite having a high level of randomization com-
prehension (RCI = 5), she expressed confusion about the 
role of probability in determining how her treatment was 
chosen. She stated, “He (health care provider) told me the 
computer would pick what group I was in, whether I would 
be in the control group or the test group (…) it’s just ran-
dom (…) It was pretty confusing.” Although Alice under-
stood randomization at a conceptual level, she did not un-
derstand why the computer would make a determination 
“at random” when information was available in her elec-
tronic medical records that could be used to match her to 
the most appropriate treatment. The relationship between 
computers and the randomization process in an RCT dem-
onstrates the tension between patient expectations of in-
dividualized care and the seemingly impersonal nature of 
how randomization was conducted.
The second procedural concern was the probability of 
receiving effective treatment in the RCT. Many patients 
misinterpreted the role of probability as the chance of re-
ceiving treatment for their cancer, not the chance of receiv-
ing one of two (or more) possible treatments. Samantha 
had high comprehension of randomization (RCI = 4) but 
declined participation in a RCT because, “There’s a possi-
bility you don’t get the proper treatment. And I think later 
on, when I talked to different people, that’s really not the 
case. I think you get—I don’t know. I’m still a bit confused 
on that.” She went on to explain that she was more com-
fortable with a more personalized treatment plan: “I just 
wanted the best—you know, I wanted to make the best 
decision. I just felt like the best decision was the known 
plan or the plan laid out by the doctor not an experimen-
tal (study).” Similarly, Kristy (RCI = 3) participated in an RCT, 
but was concerned that randomization meant that she 
might not receive treatment for her cancer:
When I signed up for (the RCT), I just worried about 
whether I was getting the drug or not getting the drug. 
You know, I’d say, ‘Well, what arm am I gonna be in?’ And I 
think I’d have probably been disappointed if I would have 
gotten the placebo. That thinking all along that maybe I’m 
taking a drug, and it’s gonna be helping me. And then to 
find out that, ‘Oh, I didn’t really get it.’
Affective Dimensions of Uncertainty about 
Randomization
Affective dimensions of uncertainty refer to the emotional 
valence of patient descriptions of randomization. Given that 
randomization entails uncertainty, we examined the extent 
to which patients used emotionally valenced terms to de-
scribe how patients would be allocated to treatment condi-
tion. As would be expected, the affective tone of random-
ization narratives ranged from neutral to negative. Neutral 
narratives were those that utilized impersonal or scientific 
explanations of equal chance in allocation to treatment arm. 
For example, Gloria, who agreed to participate in an RCT, had 
a relative strong understanding of randomization (RCI = 4). 
She was matter-of-fact in describing how randomization was 
explained to her by a health care provider (HCP) during her 
treatment decision-making process:
Some people will get the additional drug, and some won’t. 
And if you decide to sign up for the study, we (HCP) won’t 
know if you’re one of them that will get it or not until we 
get all the information entered into the computer. Then, 
it will tell us (HCPs).
Narratives reflecting a negative affective valence con-
tained implicit disapproval (e.g., sarcasm) or explicit use of 
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negative terminology to describe the randomization pro-
cess. Samantha, like Gloria, had a strong understanding 
of randomization (RCI = 4). Unlike Gloria, Samantha chose 
not to enroll in the RCT. In the following excerpt, Saman-
tha verbalizes a negative affective response to the role 
of probability in determining her treatment. Specifically, 
she uses sarcasm (“my luck”) and dehumanizing language 
(“you’re a number”) to refer to the potential of being as-
signed to the treatment arm utilizing a placebo. Finally, she 
contrasts the “placebo” treatment to arms that are “over-
aggressive” and “middle of the road” indicating she per-
ceived the RCT as offering an ineffective treatment arm 
despite her acknowledgement that patients receive treat-
ments in addition to the placebo:
One group would get this, this, and this, which is kind of 
like over aggressive and one group would get this, this, 
and this, which is kind of like your middle-of-the-road, and 
one group would get some placebos and this and this. So 
I’m thinking, ‘Well, my luck, I’ll be in the group three.’ And 
you don’t know and they don’t know (…) You’re a num-
ber and you get in a bin and we can’t say we want you to 
get this treatment or we want you to get that treatment.
In other cases, patients produced negatively valenced 
narratives as indicated by the use of specific terminology 
with a negative connotation. Cathy had a strong under-
standing of randomization (RCI = 4) but chose not to en-
roll in an RCT. She articulated her concern in the following 
way, “Had there been one thing that might have helped, I 
would have probably (enrolled in the RCT). But, they didn’t 
know that. You know, that’s why it’s a trial.” In this example, 
Cathy equates a clinical trial with the colloquialism trial 
and error, which has overtly negative connotations in the 
context of cancer treatment.
Guinea pig was another term used to express negative 
feelings toward randomization by patients at various lev-
els of randomization comprehension. For example, Tracy 
(RCI = 4) and Taylor (RCI = 1) both refused RCT participa-
tion. Tracy stated that the most influential factor in her de-
cision not to participate was “the scariness of it really not 
being approved by the FDA. You know, using something 
kind of like a guinea pig type thing.” Similarly, Taylor said, 
“You get the cutting edge treatment or drugs or whatever 
they had but then on the other hand, were you going to 
be used as a guinea pig for new stuff?” Tracy and Taylor 
illustrate that cognitive comprehension of randomization 
may be unrelated to their affective response to the process.
Discussion
RCTs are an important pathway for investigating success-
ful cancer treatments. While RCTs help reduce scientific 
uncertainty about treatment efficacy, the role of random-
ization in determining treatment increases the medical 
uncertainty of patients. The purpose of the current study 
was to explore the relationship between patient compre-
hension of randomization, treatment uncertainty, and will-
ingness to participate in cancer RCTs. We found no ev-
idence of a statistically significant association between 
randomization comprehension and participation in can-
cer RCTs. We posit that randomization comprehension is 
conceptually distinct from uncertainty, as patients with all 
levels of comprehension experienced uncertainty. Finally, 
we showed that randomization uncertainty has both cog-
nitive and affective dimensions.
Cognitive dimensions of uncertainty involved state-
ments expressing concern about how randomization 
would be accomplished and the role of probability in de-
termining treatment. These statements revealed that be-
ing assigned to treatment by chance was conceptually at 
odds with mental models of medicine grounded in an ex-
pectation of personalized care as well as the belief that 
medicine is a science and operates according to a system 
of rules and proven practices. Thus, the notion that an on-
cologist cannot choose the treatment that best matches 
the patient’s cancer in a RCT was unsettling to patients.
Affective dimensions of uncertainty were statements re-
vealing emotional reactions to the role of randomization 
in determining treatment. In some cases, patients revealed 
their emotional responses through the use of irony or sar-
casm in their descriptions of randomization while others 
used overtly negative words, such as “trial and error” and 
“guinea pig.” Addressing patient concerns and emotions 
about the safety of randomization are vital in the RCT ac-
crual process, a finding that complements and extends re-
sults from previous studies [8, 9].
An unexpected finding was that patients expressing 
both cognitive and affective dimensions of uncertainty 
had participated in a RCT. The fact that patients consented 
to participate in research despite significant uncertainty 
about treatment efficacy indicates a dire need to develop 
translational communication strategies to promote patient 
comprehension of scientific design in the medical context. 
A major source of misinformation was the belief that one 
treatment arm was superior to the others or that one arm 
was vastly inferior to the others. Given that RCTs are con-
ducted only in cases of clinical equipoise, it is noteworthy 
that patients did not view the arms as equivalent. Instead, 
patients over- or underestimated the known efficacy and 
safety of the experimental arm.
The current study benefits from a number of strengths. 
Noteworthy methodological strengths include recruiting 
an underrepresented population of Appalachian cancer 
patients who had been offered an opportunity to partic-
ipate in a cancer RCT, a substantial sample, and a rigor-
ous analytical approach. The specific focus on Appalachian 
cancer patients illuminates the potentially unique con-
cerns of rural cancer patient populations and contributes 
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an understanding of RCT recruitment among rural, Ap-
palachian cancer patients, a population that experiences 
significant cancer incidence and mortality disparities [20]. 
There are study limitations that should be noted. First, the 
generalizability of our findings beyond rural, Appalachian 
populations is limited. Furthermore, the selection criteria 
included all types of cancers and treatments; therefore, 
the results could not be generalized to studies focusing 
on a specific diagnosis(es) or particular RCTs. Future re-
search should investigate how cancer type, stage, and type 
of treatment offered is associated with the likelihood of 
participating in an RCT.
The results of the current research have important prac-
tical implications. Efforts to improve informed consent to 
participate in RCTs should focus on having patients teach 
back their understanding of randomization. This practice 
affords providers the opportunity to assess a patient’s cog-
nitive and affective understanding of randomization as well 
as opportunities to correct misperceptions. Also, education 
about RCTs should reflect patient expectations of individ-
ualized care by explaining how all treatments being com-
pared are appropriate to the specifics of a patient’s disease.
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